Cinclus Pharma Holding AB
CINPHA | ST
Overview
Corporate Details
- ISIN(s):
- SE0020388577
- LEI:
- 549300TJBPSNZ3DO6B42
- Country:
- Sweden
- Address:
- Kungsbron 1, Plan 3, trappa G, 111 22 Stockholm
- Website:
- https://cincluspharma.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Cinclus Pharma is a late clinical-stage pharmaceutical company developing advanced treatments for gastric acid-related diseases. Its lead drug candidate, linaprazan glurate, is a next-generation Potassium-Competitive Acid Blocker (P-CAB) engineered to offer a paradigm shift over traditional Proton Pump Inhibitors (PPIs). The compound is designed to provide superior clinical efficacy and a more beneficial pharmacokinetic profile for patients. The primary therapeutic targets are severe gastroesophageal reflux disease (GERD) and Helicobacter pylori (H. pylori) infection. Founded by former AstraZeneca experts, the company has successfully completed Phase II clinical trials and is advancing its lead asset towards global registration and commercialization to address significant unmet medical needs.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Cinclus Pharma Holding AB.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-20 08:00 |
Interim Report
|
Swedish | 2.6 MB | |
| 2025-08-20 08:00 |
Interim Report
|
English | 2.8 MB | |
| 2025-05-22 20:12 |
Post-Annual General Meeting Information
Beslut vid årsstämma i Cinclus Pharma Holding AB (publ) den 22 maj 2025
|
Swedish | 79.8 KB | |
| 2025-05-22 20:12 |
Post-Annual General Meeting Information
Resolutions at the Annual General Meeting in Cinclus Pharma Holding AB (publ) o…
|
English | 81.2 KB | |
| 2025-05-22 07:30 |
M&A Activity
Cinclus Pharma ingår partnerskap med Zentiva för att kommersialisera linaprazan…
|
Swedish | 93.4 KB | |
| 2025-05-22 07:30 |
M&A Activity
Cinclus Pharma Partners with Zentiva to Commercialize Linaprazan Glurate in Eur…
|
English | 92.2 KB | |
| 2025-05-20 08:00 |
Quarterly Report
|
Swedish | 2.5 MB | |
| 2025-05-20 08:00 |
Quarterly Report
|
English | 2.6 MB | |
| 2025-04-30 16:00 |
Annual Report (ESEF)
|
Swedish | 29.7 MB | |
| 2025-04-30 16:00 |
Annual Report (ESEF)
|
Swedish | 29.7 MB | |
| 2025-02-20 08:00 |
Annual Report
|
Swedish | 2.3 MB | |
| 2025-02-20 08:00 |
Annual Report
|
English | 2.3 MB | |
| 2025-01-03 17:00 |
Major Shareholding Notification
|
Swedish | 8.1 KB | |
| 2024-12-30 14:00 |
Share Issue/Capital Change
Antal aktier och röster i Cinclus Pharma
|
Swedish | 84.1 KB | |
| 2024-12-30 14:00 |
Declaration of Voting Results & Voting Rights Announcements
Number of shares and votes in Cinclus Pharma
|
English | 83.0 KB |
Automate Your Workflow. Get a real-time feed of all Cinclus Pharma Holding AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Cinclus Pharma Holding AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
